Chemomab Therapeutics (CMMB) Retained Earnings (2017 - 2025)
Chemomab Therapeutics (CMMB) posted Retained Earnings of $124.0 million for Q4 2025, up 212.95% on a QoQ basis from -$109.7 million in Q3 2025, and up 6.71% year-over-year from $116.2 million in Q4 2024.
Chemomab Therapeutics (CMMB) Retained Earnings (2017 - 2025) Analysis & Trends
Chemomab Therapeutics' Retained Earnings history runs 9 years deep, the most recent figure standing at $124.0 million for Q4 2025.
- Quarterly Retained Earnings rose 6.71% year-over-year to $124.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $124.0 million (up 6.71% YoY) and the FY2025 annual result came in at $124.0 million, up 6.71% from the prior year.
- Retained Earnings was $124.0 million for Q4 2025 at Chemomab Therapeutics, up from -$109.7 million in the prior quarter.
- Across five years, Retained Earnings topped out at $124.0 million in Q4 2025 and bottomed at -$109.7 million in Q3 2025.
- A 5-year average of $7.3 million and a median of $19.6 million in 2021 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2021 — Retained Earnings jumped 512.07% — and 2024, when it sank 190.96%.
- Chemomab Therapeutics' Retained Earnings stood at $97.6 million in 2021, then climbed by 3.71% to $101.3 million in 2022, then rose by 4.36% to $105.7 million in 2023, then rose by 9.92% to $116.2 million in 2024, then rose by 6.71% to $124.0 million in 2025.
- Business Quant data shows CMMB's Retained Earnings at $124.0 million in Q4 2025, -$109.7 million in Q3 2025, and -$108.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -27.89 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 12.91 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 115.82 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -622,000.00 |
| 10 | Chemomab Therapeutics | 124.14 Mn | 113.77 Mn | - | 123.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 123.95 Mn |
| Sep 30, 2025 | -109.75 Mn |
| Jun 30, 2025 | -108.00 Mn |
| Mar 31, 2025 | -105.95 Mn |
| Dec 31, 2024 | 116.16 Mn |
| Sep 30, 2024 | -99.66 Mn |
| Jun 30, 2024 | -96.18 Mn |
| Mar 31, 2024 | -92.55 Mn |
| Dec 31, 2023 | 105.68 Mn |
| Sep 30, 2023 | -84.62 Mn |
| Jun 30, 2023 | -80.54 Mn |
| Mar 31, 2023 | 101.74 Mn |
| Dec 31, 2022 | 101.26 Mn |
| Sep 30, 2022 | -55.55 Mn |
| Jun 30, 2022 | 99.30 Mn |
| Mar 31, 2022 | -41.28 Mn |
| Dec 31, 2021 | 97.64 Mn |
| Sep 30, 2021 | 96.65 Mn |
| Jun 30, 2021 | 96.21 Mn |
| Mar 31, 2021 | 80.56 Mn |